Abstract
The chemotherapy including the multitargeted antifolate (pemetrexed disodium; Alimta) is indicated for the 1st line treatment of patients with advanced non-small cell lung cancer (NSCLC). It is constructed by induction and maintenance chemotherapy, and some patients have the response over 12 months. We evaluated SLIT2 expression of immunohistochemistry (IHC) in NSCLC with long-term response to pemetrexed.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
